Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7021588 | 0.98 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL25256002 | 0.80 | ALDH1A1 (0.42) | ALDH1A1POLB | |
| SCHEMBL3361549 | 0.80 | ALDH1A1 (0.42) | ALDH1A1POLB | |
| SCHEMBL30678963 | 0.78 | ALDH1A1 (0.41) | ALDH1A1POLB | |
| SCHEMBL9518575 | 0.77 | ALDH1A1 (0.38) | ALDH1A1POLB | |
| SCHEMBL10966308 | 0.76 | ALDH1A1 (0.40) | ALDH1A1POLB | |
| SCHEMBL968360 | 0.76 | CHRNB2 (0.43) | ALDH1A1POLB | |
| SCHEMBL22012853 | 0.76 | ALDH1A1 (0.40) | ALDH1A1POLB | |
| SCHEMBL15500943 | 0.76 | KMT2A (0.42) | ALDH1A1 | |
| SCHEMBL11173967 | 0.76 | HTT (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128639-A1 | PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-04-27 | — | — | US | claimed |
| CN-111836811-B | Method for preparing soluble guanylate cyclase stimulators | 帝善多制药公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12054489-B2 | Substituted amidrazones as intermediates in the process for preparing soluble guanylate cyclase stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230128639-A1 | PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-04-27 | — | — | US | disclosed |
| US-11466014-B2 | Process for preparing soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-0842180-B1 | PENAM SULFONES AS BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2003-01-22 | — | — | EP | disclosed |
| EP-0842180-A1 | NOVEL PENAM SULFONES AS BETA-LACTAMASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997006172-A1 | NOVEL PENAM SULFONES AS BETA-LACTAMASE INHIBITORS | SYNPHAR LABORATORIES, INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| US-4656250-A | NORLEUCINE, TYROSINE, PHENYLALANINE TREATING HYPOPARATHYROIDISM | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-04-07 | — | — | US | disclosed |
| US-4394387-A | INSECTICIDES, MITICIDES | THE BOOTS COMPANY PLC (GB) | 1983-07-19 | — | — | US | disclosed |
| EP-0026040-A1 | Substituted benzophenone hydrazones, pesticidal compositions containing them and method of combating pests | FBC LIMITED (GB) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128639-A1 | PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | ALDH1A1 3061/4885POLB 4293/4885 |
| US-11466014-B2 | Process for preparing soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | ALDH1A1 1579/4885POLB 4709/4885 |
| US-12054489-B2 | Substituted amidrazones as intermediates in the process for preparing soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B2, PDE3A | ALDH1A1 2523/4885POLB 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.